Research-Grade Peptides | 99%+ Purity Verified | US Delivery 2–5 Days
Save 5% with Crypto
SaiyanMed

Your Cart

No products in the cart.

TB-500 Fragment vs Full: Ac-LKKTETQ vs Thymosin Beta-4 (Identity, MS & COA Guide)

A 43-bead thymosin beta-4 chain with the N-terminal four residues and the central seven-residue segment highlighted and magnified, beside a separate short seven-bead acetylated fragment shown under a magnifying circle.

Last updated: 2026-10-29 · Written by: SaiyanMed Research Team · Reviewed against: 21 primary and registry sources, all linked below

Quick answer: “TB-500” is one market name attached to two different molecules. The fragment is Ac-LKKTETQ: seven residues copied from positions 17–23 of thymosin beta-4, with an acetyl group added to the leucine (C38H68N10O14, average MW 889.0, monoisotopic 888.49 Da, CAS 885340-08-9).[3][5][7] The full form is thymosin beta-4 (Tβ4) itself: the 43-residue, N-acetylated protein (C212H350N56O78S, average MW ≈4963, monoisotopic 4960.49 Da, CAS 77591-33-4).[1][2][14] Registries and anti-doping chemists use “TB-500” for the fragment; much of the research-peptide market uses it for full-length Tβ4. The two differ by ≈4,074 Da, so a single intact-mass measurement settles which one is in a vial. The label name alone never does.

Key takeaways

  • Two molecules, one nickname. FDA, PubChem and the 2012 anti-doping papers define TB-500 as Ac-LKKTETQ. Many vendors use “TB-500” for full-length Tβ4.[3][5][7][8]
  • 5.6× size gap. 7 vs 43 residues; 889 vs ≈4963 g/mol. One milligram of fragment holds about 1.12 µmol; one milligram of full Tβ4 holds about 0.20 µmol (calculated).
  • Different chemistry, not just different length. Only the full protein carries the native acetyl-Ser1, the Ac-SDKP tetrapeptide, the oxidation-prone Met6 and both actin-contacting helices.[1][9][10][20]
  • Evidence does not transfer. The clinical-stage programmes used full-length Tβ4; FDA found no human exposure data for the fragment.[5][13]
  • What a mass spectrum shows. Fragment: m/z 889.50 (1+) and 445.25 (2+). Full Tβ4: a ladder of 4+ to 8+ ions (1241.1, 993.1, 827.8, 709.6, 621.1) that deconvolutes to ≈4963 Da (calculated).
  • HPLC purity is not identity. A 99% purity number says one peak dominates; it does not say which molecule that peak is.
  • Both are prohibited in sport. WADA S2.3 names “thymosin-β4 and its derivatives e.g. TB-500”.[11]

Contents

This page answers one practical question: which molecule is in a vial labelled “TB-500”, and how do you prove it? For the wider biology of the parent protein see TB-500 vs Thymosin Beta-4; for the limits of the preclinical record see TB-500 preclinical evidence boundaries; for the general framework of fragments, modifications and salt forms see peptide identity explained.

Where the name “TB-500” came from

Thymosin beta-4 was isolated from calf thymus and fully sequenced in 1981 by Low, Hu and Goldstein, who reported a 43-residue chain with an acetylated N-terminal serine.[12] Ten years later Safer, Elzinga and Nachmias showed that “Fx”, the main actin-monomer-binding peptide of human platelets, was the same molecule: Tβ4 forms a 1:1 complex with G-actin and blocks its polymerization.[16] That actin-sequestering role is now the best-established molecular function of Tβ4.[1]

Through the 2000s, work from Goldstein, Kleinman, Sosne and colleagues mapped several activities of Tβ4 onto short internal segments. The central stretch LKKTETQ (residues 17–23) is the actin-binding motif, and peptides containing it reproduced some cell-migration and angiogenesis readouts of the whole protein in experimental models.[9][13] A veterinary product then appeared under the trade name TB-500, described only as “the synthetic peptide of the active region of thymosin beta 4”, with no sequence or molecular weight.[18]

In 2012 two anti-doping laboratories analysed the product independently. In Ghent, Esposito and colleagues used high-resolution Orbitrap MS and saw two ions of one molecule, m/z 445.2532 ([M+2H]2+) and 889.4988 ([M+H]+), deconvoluting to 888.4910 Da. They wrote that “it was immediately evident that TB-500 did not contain the endogenous Tβ4”, then de novo sequenced the peptide as LKKTETQ with every b-ion shifted by +42.0105 Da, the signature of an N-terminal acetyl group.[7] In Hong Kong, Ho and colleagues reached the same identity and developed a detection method in horses.[8] PubChem and FDA’s substance registry (UNII QHK6Z47GTG) now attach the name TB-500 to that heptapeptide, and FDA’s 2026 compounding review defines TB-500 as “a synthetic N-acetylated heptapeptide” of residues 17–23.[3][5][6]

The research-chemical market went a different way. Many suppliers adopted “TB-500” as a short, searchable name for synthetic full-length Tβ4, and some now add “Thymosin Beta-4”, “TB4” or “43 aa” to the product title. The result is the confusion buyers see today: the same three characters mean the 7-mer in the scientific literature and, frequently, the 43-mer on a product page. Neither usage is “wrong” as a trade name; what matters is that the molecule is stated and proven.

Year Event Why it matters
1981 Bovine Tβ4 sequenced: 43 residues, Ac-Ser1[12] Defines the full molecule
1991 Tβ4 identified as the platelet G-actin sequestering peptide Fx[16] Defines its core function
2010 Active sites mapped to short sequences, incl. LKKTETQ (17–23)[9] Origin of the “active region” idea
2012 Two labs identify veterinary TB-500 as Ac-LKKTETQ[7][8] Fixes “TB-500” = fragment in the literature
2013 Equine plasma metabolite Ac-LK reported[17] Fragment metabolism
2023 Ac-Tβ1–14 proposed as a urinary marker for full Tβ4[19] Separate tests for each form
2026 FDA briefing on TB-500 free base and acetate[5][6] Regulatory definition = fragment
Timeline compiled by SaiyanMed from the cited primary sources.
Label wording you may see Most likely meaning Can you be sure from the label alone?
“TB-500 (Ac-LKKTETQ)”, “TB-500 fragment 17-23”, “TB4 frag” The 7-residue fragment Only if formula/MW (≈889) match
“Thymosin beta-4”, “Tβ4”, “TB4”, “43 aa” The 43-residue protein Only if formula/MW (≈4963) match
“TB-500” with MW ≈4963 or C212H350N56O78S Full-length Tβ4 under the market nickname Label is consistent; still verify by MS
“TB-500” with no sequence, formula or MW Unknown No
Mixed identifiers (fragment CAS with full MW, or the reverse) Contradictory label No. Ask for an intact-mass report
“TB-500” inside a blend Whatever the blend specification states Only if the blend names the form and the COA shows its mass
Interpretation guide based on registry definitions in PubChem and the FDA briefing.

TB-500 fragment vs full thymosin beta-4: structure comparison

Property TB-500 fragment (Ac-LKKTETQ) Full-length thymosin beta-4
Length 7 residues[5] 43 residues (mature, initiator Met removed)[1]
Sequence Ac-LKKTETQ-OH[3][7] Ac-SDKPDMAEIEKFDKSKLKKTETQEKNPLPSKETIEQEKQAGES-OH[1]
Position in Tβ4 Residues 17–23[5][9] 1–43
N-terminal acetyl On Leu; synthetic, not found at this position in nature[7] On Ser1; native co-translational modification[1][12]
Molecular formula C38H68N10O14[3][5] C212H350N56O78S[2]
Average MW 889.0 g/mol[5] ≈4963 g/mol[2]
Monoisotopic mass 888.4916 Da[3] 4960.486 Da[2]
Most abundant isotope peak Monoisotopic peak (M) About M+2 (≈4962.5 Da; calculated isotope pattern)
Residue composition Leu1, Lys2, Thr2, Glu1, Gln1 Lys9, Glu8, Ser4, Asp3, Pro3, Gln3, Thr3, Ala2, Ile2, Leu2, Met1, Phe1, Asn1, Gly1 (counted from UniProt sequence)
Net character Basic (two Lys, one Glu) Acidic overall (11 acidic vs 9 basic residues); historically described as an acidic 5-kDa peptide[16]
Contains Ac-SDKP (1–4)? No[9] Yes[9][10]
Contains Met (oxidation-prone)? No Yes, Met6 (+15.995 Da when oxidised)
Contains Asn (deamidation-prone)? No Yes, Asn26 (+0.984 Da when deamidated)
Solution structure Too short for stable secondary structure Largely unstructured free; forms N- and C-terminal helices when bound to G-actin[20]
Registry IDs CAS 885340-08-9; UNII QHK6Z47GTG; PubChem 62707662[3][5] CAS 77591-33-4; UNII 2D5MRE3SSY (timbetasin); UniProt P62328; PubChem 16132341 and 45382195[1][2][14][15]
Acetate salt Listed by FDA as TB-500 acetate, C38H68N10O14·CH3COOH, 949.1 g/mol[5] Often supplied as acetate; counter-ion content varies by lot
WADA Prohibited at all times (S2.3)[11] Prohibited at all times (S2.3)[11]
FDA (Oct 2026) No approved product; FDA staff recommended against the 503A bulks list[5][6] No approved product
Composition, isotope peak and modification masses calculated by SaiyanMed from the UniProt sequence using standard residue masses; other values as cited.

Two details in this table are routinely missed. First, the acetyl group sits on a different residue in each molecule: on Ser1 in natural Tβ4, but on Leu17 in the fragment, a position that is internal (and therefore unacetylated) in the parent protein. That is why Esposito et al. noted the acetylated fragment is not a known natural product and could help separate exogenous from endogenous material.[7] Second, the two molecules have opposite overall character: the fragment is a small basic peptide, while full Tβ4 is acidic. They behave differently on ion-exchange media and in reversed-phase HPLC, which is useful when reading chromatograms.

What each form contains: the functional domains

Domain map of a 43-residue peptide chain with bracketed N-terminal tetrapeptide and central actin-binding segment, magnified to show the four-residue end and the seven-residue segment resting against an actin monomer.

Reviews have assigned different activities in experimental models to short segments of Tβ4.[9][13][21] These are research observations about the protein, not claims about any product:

  • Ac-SDKP (1–4). Released from Tβ4 in two enzymatic steps, meprin-α then prolyl oligopeptidase, and studied as an anti-inflammatory and anti-fibrotic tetrapeptide.[4][10] Absent from the fragment.
  • Residues 1–15. Linked in cell studies to cell-survival signalling.[9] Absent from the fragment.
  • LKKTETQ (17–23). The central actin-binding motif; peptides containing it reproduced some migration and angiogenesis readouts.[9] This is the only region the fragment contains.
  • The flanking helices. Structural work shows bound Tβ4 stretched along G-actin, with an N-terminal helix at the barbed end and a C-terminal helix at the pointed end; the measured Kd for recombinant β-actin was 0.5 ± 0.1 µM.[20] Sequestration as described for the full protein depends on both ends, not the 17–23 motif alone.
  • Activities not localised to any short segment are also described.[9]

This is the core scientific difference. The fragment is one motif taken out of its context; the full protein carries every mapped site plus the residues that position the motif on actin. Data from one should not be used to describe the other. FDA’s 2026 review reported no human exposure data for the fragment, while the clinical-stage programmes summarised by Goldstein et al. used full-length Tβ4.[5][13]

7-mer vs 43-mer synthesis: purity, impurities and cost

Both forms are normally made by solid-phase peptide synthesis (SPPS); full Tβ4 has also been produced recombinantly in E. coli as a GST fusion for structural research.[20] Esposito et al. made the fragment by Fmoc SPPS as a reference standard, and the WADA-funded project did the same for its metabolites.[7][18] Chain length changes the chemistry of manufacturing in three ways.

1. Crude yield falls geometrically with length

Each coupling step is slightly less than 100% complete. If every step succeeds with efficiency p, the fraction of chains that are perfectly full-length is roughly pn−1. The calculation below shows why a 43-mer is far harder to make clean than a 7-mer.

Per-step coupling efficiency 7-mer: full-length fraction (p6) 43-mer: full-length fraction (p42)
98.0% 88.6% 42.8%
99.0% 94.1% 65.6%
99.5% 97.0% 81.0%
99.8% 98.8% 91.9%
Calculated by SaiyanMed; idealised model ignoring side reactions and purification losses. Real yields depend on chemistry and sequence.

The practical consequence: a crude 43-mer contains far more failure sequences than a crude 7-mer, and those impurities are similar in size and charge to the product. Getting full Tβ4 to high purity needs more preparative HPLC, more solvent and more lost material, which is why full-length Tβ4 is typically priced well above the fragment per milligram, and much more per mole (see the mass-per-mole math below).

2. Impurities you should expect to see

Impurity type Mass shift vs full Tβ4 (avg ≈4963.5) Why it matters
Deletion of one Lys (des-Lys) −128.17 → ≈4835.3 Nine Lys residues; most common deletion family
des-Gln −128.13 → ≈4835.4 Within 0.05 Da of des-Lys: only high resolution or MS/MS can tell them apart
des-Glu −129.12 → ≈4834.4 Eight Glu residues
des-Ser −87.08 → ≈4876.4 Includes loss at the N-terminus
Met6 oxidation +16.00 → ≈4979.5 Storage/handling marker
Missing N-acetyl −42.04 → ≈4921.5 Indicates an acetylation failure
Asn26 deamidation +0.98 Hard to see at intact level; needs peptide mapping
Mass shifts calculated by SaiyanMed from average residue masses; illustrative, not lot data.

For the 7-mer the equivalent impurities (for example des-Lys at ≈760.8 or non-acetylated LKKTETQ at [M+H]+ 847.49, calculated) are easy to resolve because each one is a large fraction of the molecule. That is the analytical flip side of synthesis difficulty: short peptides are easy to make clean and easy to characterise; long ones are hard to make clean and need better instruments to prove it.

3. Same milligrams, very different molecule counts

Quantity on label Ac-LKKTETQ (889.0 g/mol) Full Tβ4 (≈4963 g/mol)
1 mg 1.12 µmol 0.20 µmol
2 mg 2.25 µmol 0.40 µmol
5 mg 5.62 µmol 1.01 µmol
10 mg 11.25 µmol 2.01 µmol
Calculated by SaiyanMed from free-base molecular weights. Counter-ion and water content reduce the true peptide amount further; see net peptide content in our salt-form guides.

In other words, “10 mg TB-500” can mean a 5.6-fold difference in the number of molecules depending on the form. Counter-ions add another layer: salt forms change how much of the weighed powder is peptide, as explained in our BPC-157 acetate vs arginate analysis.

Identity by mass spectrometry: the full m/z tables

Two schematic mass spectra: a short peptide giving a few low-m/z peaks, and a 43-residue protein giving a ladder of multiply charged isotope envelopes, each magnified.

Electrospray ionisation (ESI) adds protons to a molecule, so an ion appears at m/z = (M + z × 1.00728) / z. A small peptide carries one or two charges. A 5-kDa protein has no free N-terminal amine (Ser1 is acetylated), but its nine lysines still let it pick up four to eight protons, producing a charge-state ladder. Software then “deconvolutes” the ladder back to a single neutral mass.

Charge state Fragment: monoisotopic m/z Fragment: average m/z Full Tβ4: monoisotopic m/z Full Tβ4: average m/z
1+ 889.499 890.02 4961.49 4964.5
2+ 445.253 445.52 2481.25 2482.8
3+ 297.171 297.35 1654.50 1655.5
4+ — — 1241.13 1241.9
5+ — — 993.10 993.7
6+ — — 827.76 828.3
7+ — — 709.65 710.1
8+ — — 621.07 621.4
Calculated by SaiyanMed from PubChem/UniProt-derived monoisotopic and average masses (proton 1.007276 Da). Expected values, not measured lot data. Low-resolution instruments report values near the average column; high-resolution instruments resolve isotope peaks.

How these numbers match the literature: Esposito et al. measured the fragment at m/z 445.2532 (2+) and 889.4988 (1+) on an Orbitrap, within 1 ppm of our calculated monoisotopic values, and used the 445.5 precursor (low resolution) for triple-quadrupole SRM with product ions at m/z 129 and 606.4.[7]

How to read a mass result in four steps

  1. Find the expected mass on the report. ≈889 means the report is set up for the fragment; ≈4963 for full Tβ4. A report whose expected mass does not match the product name is the first red flag.
  2. Look at where the observed peaks sit. Strong peaks at 889/445 with nothing above m/z ≈1000 indicate a small molecule of fragment size. A family of peaks between ≈600 and ≈1300 spaced like 1241 / 993 / 828 / 710 indicates a ≈5-kDa protein.
  3. Check the deconvoluted mass. For full Tβ4 it should be within a few Da of 4963 (average) or 4960.5 (monoisotopic). Labs may report the most abundant isotope (≈4962.5), so a 1–3 Da difference from the monoisotopic value is normal.
  4. Explain every extra peak. +16 Da suggests Met oxidation; −128 suggests a deletion; +22 a sodium adduct; −42 a missing acetyl group.

One pitfall deserves a sentence of its own: a full-length protein ladder never contains a peak at m/z 889.5 as part of its own charge series, because (4960.49 + z×1.007)/z does not equal 889.5 for any integer z (z = 5 gives 993.1; z = 6 gives 827.8). A dominant 889.5 / 445.3 pair therefore points to a molecule of fragment mass in the sample, whatever the label says. Conversely, an in-source fragment or a minor impurity can appear at unexpected m/z values, which is why a good report shows the whole spectrum and states which peaks were assigned.

HPLC retention: supportive only

A 7-mer and a 43-mer normally elute at different times on reversed-phase HPLC, but retention depends on column, gradient, temperature and ion-pairing agent, so a retention time from one lab means little in another. HPLC answers “how pure is the main peak?”; MS answers “what is the main peak?”. A credible identity claim needs both, from the same lot.

MS/MS and peptide mapping: the strongest proof

Tandem MS fragments the peptide along its backbone. For the fragment, the complete b- and y-ion series confirms LKKTETQ, and every b-ion is shifted by +42.01 Da by the acetyl cap.[7] For full Tβ4, laboratories usually digest the protein (for example with trypsin or Glu-C) and sequence the pieces. Peptide mapping confirms the Ac-SDKP N-terminus, checks Met6 oxidation and Asn26 deamidation, and can distinguish near-isobaric deletions such as des-Lys and des-Gln that intact mass cannot.

How to read a TB-500 COA: checklist and red flags

A certificate of analysis is only as useful as the identity test behind it. Use this checklist for any vial labelled TB-500, from any supplier. For general COA reading see how to read a peptide COA and what mass spectrometry can and cannot confirm.

  1. The molecule is named, not just the nickname. “Ac-LKKTETQ” or “thymosin beta-4, 43 aa”. “TB-500” alone is not an identity.
  2. Expected MW matches the named molecule: ≈889 (fragment free base), 949.1 (fragment acetate, labelled as salt), or ≈4963 (full Tβ4 free base).
  3. Observed mass is shown as a spectrum image, a peak list or a deconvoluted mass, and agrees with the expected value within the lab’s stated tolerance.
  4. The spectrum is consistent with the size claimed: a charge ladder for a ≈5 kDa protein, or 1+/2+ ions for a ≈0.9 kDa peptide (see the m/z table).
  5. Purity and content are separate results, each with a named method (HPLC-UV for purity; quantitation by HPLC against a standard or by amino-acid analysis for content).
  6. CAS and formula match the molecule: 885340-08-9 / C38H68N10O14 for the fragment; 77591-33-4 / C212H350N56O78S for full Tβ4.
  7. The lot number on the report matches the vial, and the issuing laboratory can confirm the report.
Red flag What it usually means What to ask for
Product says “thymosin beta-4” but expected MW on report ≈889 The report or the product is mislabeled Intact-mass result with expected ≈4963
Only a purity % is reported Identity was not tested Any MS result for that lot
Quantity-only report naming “TB-500 (TB4)” without a mass Identity is assumed from the name Intact mass or MS/MS
Observed main peaks at 889 / 445 for a product sold as full-length A fragment-sized molecule was detected Ask the lab to confirm the assignment; request intact-mass analysis targeting ≈4963
Deconvoluted mass ≈4979 as the main species Largely Met-oxidised material Repeat test; check storage
Several peaks 128 Da apart below 4963 Deletion impurities Higher-resolution MS or peptide mapping
Same COA image used for many lot numbers Report not lot-specific A dated, lot-matched report
Fragment CAS 885340-08-9 printed next to MW 4963 (or the reverse) Copy-paste labelling Corrected specification sheet
Red-flag guide compiled by SaiyanMed. A red flag is a reason to ask questions, not proof of a problem.

Two cautions keep this fair. Laboratories differ in how they label peaks and which charge states they list, so a confusing report is a reason to ask the lab, not proof of fraud. And many quantity-only reports simply do not test identity at all; they confirm how much peptide-like material is present, not which molecule it is.

What anti-doping science tells us about the two forms

Anti-doping chemistry is the most rigorous public source on TB-500 identity, because laboratories must prove exactly which molecule they detect. Three findings stand out:

  • The fragment is metabolised from its C-terminus. Ho et al. found the parent peptide and metabolites in horse urine and plasma in samples collected after horses received a single administration of a product containing 10 mg Ac-LKKTETQ, with detection limits of 0.01 ng/mL (urine) and 0.02 ng/mL (plasma).[8] A follow-up multi-peptide method detected Ac-LKKTETQ and its metabolite Ac-LK in horse plasma.[17] A WADA-funded human in-vitro study found the same pattern, serial C-terminal cleavage with the acetylated N-terminus protected, and synthesised reference standards for metabolites M(1-2), M(1-3) and M(1-5), with urinary LODs of 500, 100 and 50 pg/mL.[18]
  • Full Tβ4 needs a different marker. Because healthy people carry endogenous Tβ4 in blood, detecting the intact protein does not show outside origin. Rahaman et al. therefore proposed the N-terminal metabolite Ac-Tβ1–14 ([M+3H]3+ m/z 565.595) as a urinary marker in rats, detectable up to 48 h and absent from eight blank human urines; LOD 0.19 ng/mL.[19]
  • The acetyl position separates the forms. The non-acetylated 17–23 sequence can arise naturally from Tβ4 breakdown, but the Leu-acetylated version is not a described natural product, which helps laboratories identify synthetic fragment.[7]
Analyte Formed from Calculated [M+H]+ (mono) Source
Ac-LKKTETQ (parent) Fragment 889.499 [7][8]
Ac-LKKTE (M1-5) Fragment 660.393 [18]
Ac-LKK (M1-3) Fragment 430.302 [18]
Ac-LK (M1-2) Fragment 302.207 [17][18]
Ac-Tβ1–14 (Ac-SDKPDMAEIEKFDK) Full Tβ4 [M+3H]3+ 565.60 (reported 565.595) [19]
Masses calculated by SaiyanMed from monoisotopic residue masses; analytes as reported in the cited studies.

For a buyer, the lesson is simple: the scientists with the most at stake treat the fragment and the full protein as two different analytes with two different metabolic fingerprints. A product description should be equally precise.

TB-500 in blends: what the label can and cannot tell you

TB-500 is often combined with BPC-157 and other peptides in multi-component research blends. In a blend the form matters even more:

  • Molar ratios change about 5.6-fold with the form. “10 mg TB-500” is about 11.2 µmol of fragment, but only about 2.0 µmol of full Tβ4 (calculated, free base).
  • The blend specification should name the form, and its COA should list the expected mass for that component.
  • Blend spectra contain every component. Look for the TB-500 component specifically: a ≈4963 Da deconvoluted mass for full Tβ4, or 889 / 445 ions for the fragment. A single purity figure for the whole mixture does not establish the identity of each component.
  • Smaller partners can mask or mimic peaks. BPC-157 (≈1419 Da) gives 2+ and 3+ ions in the same m/z region as Tβ4’s higher charge states, so blend reports should assign peaks to components explicitly. See our BPC-157 research guide for that molecule’s identity data.

Which TB-500 form does SaiyanMed use?

SaiyanMed labels by the full protein, not the fragment. Our standalone TB-500 (thymosin beta-4) and the TB-500 component in every blend that contains it, including the KLOW, GLOW and Wolverine stacks, are full-length 43-residue thymosin beta-4 (C212H350N56O78S, ~4963 g/mol, CAS 77591-33-4), not the Ac-LKKTETQ fragment.[2][14] We keep the name “TB-500” because it is how the market searches, while acknowledging that registries and the analytical literature use “TB-500” for the 7-residue fragment. In our blends, “10 mg TB-500” therefore means 10 mg of full-length thymosin beta-4, about 2.0 µmol (calculated).

Whatever the supplier, the checklist above still applies: compare each lot’s report against the expected full-length mass. Lot reports are collected in the SaiyanMed Trust Center.

Myths vs evidence

Myth Evidence
“TB-500 is just synthetic thymosin beta-4.” By registry and literature definition TB-500 is Ac-LKKTETQ; many vendors use the name for full Tβ4. Check the formula.[3][5][7]
“The fragment is the active part, so it does everything Tβ4 does.” Not shown. It lacks Ac-SDKP, residues 1–15 and the actin-contacting helices; only some readouts were reproduced in experimental models.[9][20]
“Thymosin beta-4 clinical trials apply to TB-500.” Those programmes used full-length Tβ4. FDA found no human exposure data for the fragment.[5][13]
“The fragment weighs about 860 (or 878) Da.” Its average MW is 889.0 g/mol, monoisotopic 888.49 Da; the acetate salt is 949.1.[3][5]
“99% HPLC purity proves it is the right TB-500.” Purity says one peak dominates; only MS (ideally MS/MS) says which molecule it is.
“Same mg means same amount.” 1 mg fragment ≈1.12 µmol; 1 mg full Tβ4 ≈0.20 µmol (calculated).
“A blue/white powder or price tells you the form.” Appearance and price cannot identify a peptide; both forms are white lyophilised powders.
“If the COA says TB-500, identity was tested.” Many reports are quantity-only and assume identity from the name.
“Only the fragment is banned in sport.” WADA S2.3 names thymosin-β4 and its derivatives, e.g. TB-500.[11]
“Acetylation on the fragment makes it natural.” Natural Tβ4 is acetylated on Ser1; the Leu-acetylated 17–23 peptide is not a described natural product.[7]
Evidence summary by SaiyanMed Research Team.

Glossary

  • Thymosin beta-4 (Tβ4): 43-residue N-acetylated protein that binds monomeric G-actin.
  • TB-500: market/trade name; in registries, Ac-LKKTETQ; in many vendor catalogues, full Tβ4.
  • Ac-LKKTETQ: the acetylated 17–23 heptapeptide of Tβ4.
  • Ac-SDKP: N-terminal tetrapeptide (residues 1–4) released from Tβ4 by enzymes.
  • Monoisotopic mass: mass using only the lightest isotope of each element; what high-resolution MS measures for small peptides.
  • Average MW: mass weighted by natural isotope abundance; used for weighing and molar math.
  • Charge state (z): number of protons added in ESI; m/z = (M + z·1.00728)/z.
  • Deconvolution: software step that converts a charge-state ladder back to one neutral mass.
  • MS/MS: tandem MS; breaks the peptide to read its sequence (b- and y-ions).
  • Peptide mapping: digesting a protein and sequencing the pieces to confirm the full sequence and modifications.
  • Deletion sequence: SPPS impurity missing one residue.
  • Net peptide content: share of the weighed powder that is peptide, after counter-ions and water.
  • SPPS: solid-phase peptide synthesis, the standard chemical route for both forms.
  • LOD: limit of detection.

Frequently asked questions

What is the difference between TB-500 fragment and full TB-500?

The fragment is Ac-LKKTETQ: 7 residues, about 889 g/mol, matching residues 17–23 of thymosin beta-4. “Full” TB-500 is market shorthand for full-length thymosin beta-4: 43 residues, about 4963 g/mol, CAS 77591-33-4.

Is TB-500 the same as thymosin beta-4?

Not by registry definition. PubChem, FDA’s substance registry and the 2012 anti-doping papers define TB-500 as the acetylated 17–23 fragment. Many research suppliers, however, use the name for full-length thymosin beta-4, so always check the formula and molecular weight.

What is the sequence of the TB-500 fragment?

Ac-Leu-Lys-Lys-Thr-Glu-Thr-Gln-OH (Ac-LKKTETQ), formula C38H68N10O14, CAS 885340-08-9 for the free base.

What is the molecular weight of thymosin beta-4?

About 4963 g/mol average (C212H350N56O78S), monoisotopic 4960.49 Da. The most abundant isotope peak is about 2 Da higher than the monoisotopic mass.

Which mass spec peaks indicate the TB-500 fragment?

The fragment gives [M+H]+ at m/z 889.50 and [M+2H]2+ at m/z 445.25 (monoisotopic). Full thymosin beta-4 gives a multiply charged ladder, for example 993.1 (5+), 827.8 (6+) and 709.6 (7+), deconvoluting to about 4963 Da.

How can I tell which TB-500 form is in a vial?

Use intact-mass LC-MS from the same lot, ideally with MS/MS. HPLC purity alone cannot tell the two forms apart, and neither can appearance or price.

Why is full-length thymosin beta-4 more expensive than the fragment?

It is six times longer, so solid-phase synthesis produces more failure sequences and needs more purification. Per mole the gap is larger still, because 1 mg of full Tβ4 contains about one-sixth as many molecules as 1 mg of fragment.

Does the TB-500 fragment contain Ac-SDKP?

No. Ac-SDKP is residues 1–4 of thymosin beta-4. The fragment covers residues 17–23 only.

How do anti-doping labs detect TB-500?

For the fragment, LC-MS methods target Ac-LKKTETQ and its C-terminally shortened metabolites such as Ac-LK, Ac-LKK and Ac-LKKTE. For full thymosin beta-4, a 2023 rat study proposed the metabolite Ac-Tβ1–14 as a urinary marker.

Is TB-500 banned by WADA?

Yes. The WADA Prohibited List names “thymosin-β4 and its derivatives e.g. TB-500” under S2.3, prohibited at all times.

Is SaiyanMed TB-500 the fragment or full-length thymosin beta-4?

Full-length. SaiyanMed’s standalone TB-500 and the TB-500 component in its blends (KLOW, GLOW, Wolverine) are full-length 43-residue thymosin beta-4, about 4963 g/mol, CAS 77591-33-4, not the Ac-LKKTETQ fragment. For any supplier’s blend, check that the COA lists the expected mass for the form it claims.

Where to go next

For the biology of the parent protein, read TB-500 vs Thymosin Beta-4. For what animal and cell studies can and cannot support, see TB-500 preclinical evidence boundaries. A different thymic peptide is profiled in What is thymosin alpha-1. Before relying on any lot, compare its report with the checklist above and use the Trust Center to find lot documentation.

About the author: This guide was written by the SaiyanMed Research Team. The team reviews primary literature, registry records and third-party test reports for the compounds we list. Every identity and regulatory claim above links to its source, and every calculated value is labelled as calculated. For research use only.

Last updated: 2026-10-29

References

  1. UniProt P62328: Thymosin beta-4 (TMSB4X), human
  2. PubChem CID 45382195: Thymosin beta-4
  3. PubChem CID 62707662: TB-500 (Ac-LKKTETQ)
  4. PubChem CID 65938: Goralatide (Ac-SDKP)
  5. FDA. Briefing document: TB-500-related bulk drug substances (TB-500 free base and TB-500 acetate). Pharmacy Compounding Advisory Committee, July 2026
  6. FDA. July 23–24, 2026 meeting of the Pharmacy Compounding Advisory Committee
  7. Esposito S, Deventer K, Goeman J, Van der Eycken J, Van Eenoo P. Synthesis and characterization of the N-terminal acetylated 17–23 fragment of thymosin beta 4 identified in TB-500, a product suspected to possess doping potential. Drug Test Anal 2012;4:733–738
  8. Ho EN, Kwok WH, Lau MY, et al. Doping control analysis of TB-500, a synthetic version of an active region of thymosin β4, in equine urine and plasma by liquid chromatography–mass spectrometry. J Chromatogr A 2012;1265:57–69
  9. Sosne G, Qiu P, Goldstein AL, Wheater M. Biological activities of thymosin β4 defined by active sites in short peptide sequences. FASEB J 2010;24:2144–2151
  10. Kumar N, Nakagawa P, Janic B, et al. The anti-inflammatory peptide Ac-SDKP is released from thymosin-β4 by renal meprin-α and prolyl oligopeptidase. Am J Physiol Renal Physiol 2016
  11. World Anti-Doping Agency. Prohibited List, S2.3 (thymosin-β4 and its derivatives e.g. TB-500)
  12. Low TL, Hu SK, Goldstein AL. Complete amino acid sequence of bovine thymosin β4: a thymic hormone that induces terminal deoxynucleotidyl transferase activity in thymocyte populations. PNAS 1981;78:1162–1166
  13. Goldstein AL, Hannappel E, Sosne G, Kleinman HK. Thymosin β4: a multi-functional regenerative peptide. Basic properties and clinical applications. Expert Opin Biol Ther 2012;12:37–51
  14. PubChem CID 16132341: Timbetasin (thymosin beta-4), CAS 77591-33-4
  15. FDA Global Substance Registration System, UNII 2D5MRE3SSY: Timbetasin
  16. Safer D, Elzinga M, Nachmias VT. Thymosin β4 and Fx, an actin-sequestering peptide, are indistinguishable. J Biol Chem 1991;266:4029–4032
  17. Kwok WH, Ho EN, Lau MY, et al. Doping control analysis of seven bioactive peptides in horse plasma by liquid chromatography–mass spectrometry. Anal Bioanal Chem 2013;405:2595–2606
  18. WADA-funded project. Investigation of in vitro/ex vivo TB-500 metabolism, synthesis of relevant metabolites and detection limits in urine and plasma
  19. Rahaman KA, et al. Detection and quantification of the metabolite Ac-Tβ1–14 in in vitro experiments and urine of rats treated with Ac-Tβ4: a potential biomarker of Ac-Tβ4 for doping tests. Drug Test Anal 2023;15:1454–1467
  20. Huang S, et al. Utilization of paramagnetic relaxation enhancements for structural analysis of actin-binding proteins in complex with actin. Sci Rep 2016;6:33690
  21. Xing Y, Ye Y, Zuo H, Li Y. Progress on the function and application of thymosin β4. Front Endocrinol 2021;12:767785

Research Use Only Disclaimer

This article is for laboratory and analytical education only. All SaiyanMed products are sold strictly for in-vitro research use only (RUO). They are not drugs, foods, supplements or cosmetics and are not for human or animal use. Nothing here is medical advice, a protocol for administration, or a claim about any effect. Regulatory and literature information is cited for scientific context only.